Objective: It seems that neuroendocrine breast carcinoma (NEBC) is underrecognized in routine practice. 2003 World Health Organization classification of tumors of the breast defined NEBC as a subtype of invasive mammary carcinoma in which >50 % of the tumor cells express neuroendocrine markers. Three cases compatible with solid NEBC are discussed with an emphasis on identifying features useful in recognition of this tumor type. Results: The patients were 35, 55 and 57 years old women. All patients presented with a palpable mass, two in the right and one in the left breast. Microscopically, infiltrating, solid cohesive nesting pattern with delicate sinusoidal vasculature or peliosis and papillary pattern were observed. The tumor cells were round or polygonal with abundant granular, eosinophilic cytoplasm. The nuclei had hyperchromatic/vesicular or "salt and pepper" chromatin. Two cases had ductal carcinoma in situ component. All cases were positive for synaptophysin and chromogranin A in >50 % of tumor cells. While a positive status for estrogen receptor was detected in all cases, progesterone receptor was observed in two cases. None of the tumors displayed HER2 overexpression. Conclusion: Morphological clues suggestive of NEBC must be recognized for immunohistochemical confirmation for appropriate classification of this clinically distinct subtype of invasive breast carcinoma. Objective: Automation of HER2 FISH may improve HER2 gene testing. The aim of our study was to evaluate an automated HER2 FISH assay for assessing the HER2 genomic status. Method: Core biopsies of 100 invasive breast carcinomas were analysed in parallel using the manual PathVysion™ HER-2 DNA Probe Kit and the automated Leica HER2 FISH System for the BOND™ instrument. To assess intermethod agreement, concordance analysis was performed for various numerical and categorical parameters. Results: Carcinomas with all HER2 immunohistochemical scores were included (0+: 20; 1+: 20; 2+: 30; 3+: 30). Using either HER2/CEP 17 ratio >2.2 or ≥2.0 as criterion for HER2 amplification, high levels of concordance were observed between automated and manual FISH (concordance rate 96 %, K coefficient 0.92). High levels of inter-method agreement were also found for HER2 copy number, CEP17 copy number, HER2/CEP17 ratio, the percentage of carcinoma cells with HER2/CEP17 ratio >2.2, and the presence of HER2 genetic heterogeneity, HER2 clusters and CEP17 polyploidy. Conclusion: HER2 testing using automated FISH is feasible on breast carcinoma core biopsies. Automated HER2 FISH using the Leica HER2 FISH System for BOND is an alternative to manual HER2 FISH in evaluating the HER2 status of primary invasive breast carcinomas.